When it rains, it pours, and for big pharma, it certainly poured in the third quarter.
Keep Reading →
October 20 - Hedge Funds, News
Shares of Twitter Inc (NYSE:TWTR) and Biogen Inc (NASDAQ:BIIB) are up by 4% and 2.4% respectively in afternoon trading, as investors become more optimistic about the two companies...
Keep Reading →
October 7 - Market Movers, News
Among all the insider buying and selling activity yesterday, we identified three companies which had a large volume of insider purchases in terms of monetary value, either by ...
Keep Reading →
July 28 - Hedge Funds, Insider Trading, News
The shares of Biogen Inc (NASDAQ:BIIB) were down by 21.52% after missing analysts’ revenue expectations for the quarter and slashing its revenue guidance for the full fiscal...
Keep Reading →
July 24 - Hedge Funds, Market Movers, News
Billionaire Stanley Druckenmiller, a PhD from the University of Michigan, is one of the titans of the hedge fund industry.
Keep Reading →
May 19 - Hedge Funds, News
Krishen Sud’s Sivik Global Healthcare has filed its latest 13F with the SEC, disclosing the holdings in its equity portfolio as of March 31.
Keep Reading →
April 24 - Hedge Funds, News
Stanley Druckenmiller’s Duquesne Capital easily outpaced the timid Q1 market, in which the S&P 500 returned just 0.9%.
Keep Reading →
April 22 - Hedge Funds, News
Paul Sinclair's newly established healthcare-focused fund, Blue Jay Capital Management posted an impressive 12% return during the first quarter, significantly outperforming the...
Keep Reading →
April 14 - Hedge Funds, News
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Keep Reading →
March 26 - Hedge Funds, News
In the last couple of years, biotechnology industry has been a hot topic and investors have been watching closely as the industry gained on average 40% in the last three years...
Keep Reading →
March 23 - Hedge Funds, News
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February.
Keep Reading →
March 2 - Hedge Funds, News
With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.
Keep Reading →
February 23 - Hedge Funds, News
Billionaire Stanley Druckenmiller’s Duquesne Capital revealed its top 5 picks going into 2015 last week. According to the 13F Form filed with the U.S.
Keep Reading →
February 16 - Hedge Funds, News
Biogen Idec Inc (NASDAQ:BIIB) might be a step closer in finding a cure for Alzheimer's, as the company revealed some promising progress on that front today, which also saw the...
Keep Reading →
December 2 - News
Biogen Idec Inc (NASDAQ:BIIB) and Gilead Sciences, Inc.
Keep Reading →
September 6 - News, Stock Analysis
Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.
Keep Reading →
August 28 - Hedge Funds, News
Corporate earnings season is already in full swing presenting an opportunity to watch the headline revenues and earnings per share of stocks in the market affected by various ...
Keep Reading →
July 24 - News
In the back drop of the biotech S&P ETF impacted by the S&P shedding market valuation by close to 7 % this week, Robyn Karnauskas who heads Deutsche Bank’s biotechnology vertical...
Keep Reading →
July 9 - News, Stock Analysis
Ghost Tree Capital is a healthcare-oriented hedge fund headquartered in New York.
Keep Reading →
February 27 - Hedge Funds, News
New York City-based Iguana Healthcare Management was founded by Stuart Weisbrod in 2010.
Keep Reading →
February 25 - Hedge Funds, News
Rock Springs Capital Management is a Baltimore-based hedge fund founded in February 2013 by Kris Jenner. Prior to that, Jenner had spent 14 years working at T.
Keep Reading →
February 24 - Hedge Funds, News
Renaissance Technologies has had one of the most successful histories of any hedge fund tracked by Insider Monkey.
Keep Reading →
November 14 - Hedge Funds, News
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the ...
Keep Reading →
September 20 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
September 17 - News
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Keep Reading →
September 17 - News
For the latest deal, Biogen Idec Inc (NASDAQ:BIIB) is giving Isis $100 million up front, and ISIS Pharmaceuticals, Inc.
Keep Reading →
September 11 - News
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 10 - News
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years.
Keep Reading →
September 10 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 9 - News
Based on today's economic data, you would certainly have expected a more robust rally than what the broad-based S&P 500 (INDEXSP:.INX) ended up gaining, but beggars can't be...
Keep Reading →
September 4 - News
In the financial blogosphere, there are a lot of analytical tools for Biogen Idec Inc.
Keep Reading →
August 31 - News
As an investor in the health care sector, it can sometimes feel like everything -- and everyone -- is out to get you.
Keep Reading →
August 30 - News
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News
While Carl Icahn’s team overseeing his investment in Nuance Communications Inc.
Keep Reading →
August 26 - Hedge Funds
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Keep Reading →
August 19 - News
The performance of Baxter International Inc. (NYSE:BAX), the world’s second-largest maker of dialysis products, has been lagging the market with 7.38% gain YTD as of Aug 2, ...
Keep Reading →
August 10 - News
Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease.
Keep Reading →
August 8 - News
Recently, Elan Corporation, plc (ADR) (NYSE:ELN) ended the fight against bids from Royalty Pharma.
Keep Reading →
August 7 - News
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Keep Reading →
August 1 - News
Pharmacyclics, Inc. (NASDAQ:PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share.
Keep Reading →
August 1 - News
Three months ago after Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced its first-quarter financial results, I asked if those results were as bad as they looked.
Keep Reading →
July 31 - News
When I interviewed Alkermes Plc (NASDAQ:ALKS)' CEO Richard Pops last year, he described the relocation of the company's headquarters to Ireland where taxes are lower after buying...
Keep Reading →
July 30 - News
Investors weren't blown away with today's data, which is understandable since there wasn't anything too meaningful released.
Keep Reading →
July 30 - News
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.
Keep Reading →
July 29 - News